THE ROLE OF MYOKINES INTERSTITIAL INTERACTION AND REGULATION OF METABOLISM: A REVIEW OF LITERATURE
Abstract
References
1. Pedersen BK, Åkerström TC, Nielsen AR, et al. Role of myokines in exercise and metabolism. J Appl Physiol (1985). 2007 Sep;103(3): 1093-1098. doi: 10.1152/ japplphysiol.00080.2007. Epub 2007 Mar 8.
2. Гребенникова Т.А., Белая Ж.Е., Цориев Т.Т., и др. Эндокринная функция костной ткани // Остеопороз и остеопатии. - 2015. - №1. - С. 28-37. [Grebennikova TA, Belaya ZhE, Tsoriev TT, et al. Endocrine function of bone tissue. Osteoporoz i osteopatii. 2015;(1):28-37. (In Russ)]
3. Белая Ж. Е., Смирнова О. М., Дедов И. И. Роль физических нагрузок в норме и при сахарном диабете // Проблемы эндокринологии. - 2005. - Т.51. - №2. - С. 28-37. [Belaya ZhE, Smirnova OM, Dedov II. Rol’ fizicheskikh nagruzok v norme i pri sakharnom diabete. (Role of exercise in health and in diabetes mellitus.) Problemy endokrinologii. 2005;51(2):28-37. (In Russ)]
4. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev. 2008;88:1379-1406. doi:10.1152/physrev.90100.2007.
5. Pedersen BK. The diseasome of physical inactivity and the role of myokines in muscle-fat cross talk. J Physiol. 2009;587(Pt 23):5559-5568. doi: 10.1113/jphysiol.2009.179515. Epub 2009 Sep 14. Review.
6. Borg SA, Kerry KE, Baxter L, et al. Expression of interleukin-6 and its effects on growth of HP75 pituitary tumour cells. J Clin Endocrinol Metab. 2003;88:4938-4944. doi: 10.1210/jc.2002-022044.
7. van Hall G, Steensberg A, Sacchetti M, et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab. 2003;88:3005-3010. doi: 10.1210/ jc.2002-021687.
8. Kelly M, Keller C, Avilucea PR, et al. AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun. 2004;320:449-454. doi: 10.1016/j.bbrc.2004.05.188.
9. Wallenius V, Wallenius K, Ahrén B, et al. Interleukin- 6-deficient mice develop mature-onset obesity. Nat Med. 2002;8:75-79. doi: 10.1038/nm0102-75.
10. Febbraio MA, Hiscock N, Sacchetti M, et al. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes. 2004;53:1643-1648.
11. Banzet S, Koulmann N, Simler N, et al. Control of gluconeogenic genes during intense/prolonged exercise: hormone-independent effect of muscle-derived IL-6 on hepatic tissue and PEPCK mRNA. J Appl Physiol. 2009; 107: 1830-1839. doi:10.1152/japplphysiol.00739.2009.
12. Bouzakri K, Plomgaard P, Berney T, et al. Bimodal effect on pancreatic β-cells of secretory products from normal or insulin-resistant human skeletal muscle. Diabetes. 2011;60:1111-1121. doi:10.2337/db10-1178.
13. Gopurappilly R, Bhonde R. Can multiple intramuscular injections of mesenchymal stromal cells overcome insulin resistance offering an alternative mode of cell therapy for type 2 diabetes? Med Hypotheses. 2012;78:393-395. doi:10.1016/j. mehy.2011.11.021.
14. Ellingsgaard H, Hauselmann I, Schuler B, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med. 2011;17:1481-1489. doi:10.1038/nm.2513.
15. Nehlsen-Cannarella SL, Fagoaga OR, Nieman DC, et al. Carbohydrate and the cytokine response to 2.5 h of running. J Appl Physiol. 1997;82:1662-1667.
16. Pedersen BK, Steensberg A, Fischer C, et al. Searching for the exercise factor: is IL-6 a candidate? J Muscle Res Cell Motil. 2003;24:113-119.
17. Pedersen L, Pilegaard H, Hansen J, et al. Exercise-induced liver chemokine CXCL-1 expression is linked to muscle-derived interleukin-6 expression. J Physiol. 2011;589:1409-1420. doi:10.1113/jphysiol.2010.200733.
18. Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463-468. doi:10.1038/nature10777.
19. Uldry M, Yang W, St-Pierre J, et al. Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiation. CellMetab. 2006 May;3(5):333-341. doi: 10.1016/j.cmet.2006.04.002.
20. Arany Z, He H, Lin J, et al. Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab. 2005 Apr;1(4):259-271. doi: 10.1016/j.cmet.2005.03.002.
21. Lin J, Wu PH, Tarr PT, et al. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell. 2004 Oct 1;119(1): 121-135. doi: 10.1016/j. cell.2004.09.013.
22. Cui S, Tanabe O, Lim KC, et al. PGC-1 coactivator activity is required for murine erythropoiesis. Mol Cell Biol. 2014 Jun;34(11): 1956-1965. doi: 10.1128/MCB.00247-14. Epub 2014 Mar 24.
23. Ma D, Li S, Lucas EK, et al. Neuronal inactivation of peroxisome proliferator-activated receptor y coactivator 1a (PGC-1 a) protects mice from diet-induced obesity and leads to degenerative lesions. JBiolChem. 2010 Dec 10;285(50):39087-39095. doi: 10.1074/jbc.M110.151688. Epub 2010 Oct 13.
24. Rana KS, Arif M, Hill EJ, et al. Plasma irisin levels predict telomere length in healthy adults. Age (Dordr). 2014 Apr;36(2):995-1001. doi: 10.1007/s 11357-014-9620-9. Epub 2014 Jan 29.
25. Gaussin V, Depre C. Myostatin, the cardiac chalone of insulin-like growth factor-1. Cardiovasc Res. 2005;68:347-349. doi: 10.1016/j.cardiores.2005.09.007.
26. Shyu KG, Ko WH, Yang WS, et al. Insulin-like growth factor-1 mediates stretch-induced upregulation of myostatin expression in neonatal rat cardiomyocytes. Cardiovasc Res. 2005;68:405-414. doi: 10.1016/j.cardiores.2005.06.028.
27. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387:83-90. doi: 10.1038/387083a0.
28. Sharma M, Kambadur R, Matthews K, et al. Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. J Cell Physiol. 1999;180:1-9. doi: 10.1002/ (SICI)1097-4652(199907)180:1<1::AID-JCP1>3.0.CO;2-V.
29. Kanzleiter T, Rath M, Görgens SW, et al. The myokine decorin is regulated by contraction and involved in muscle hypertrophy. Biochem Biophys Res Commun. 2014 Jul 25;450(2): 1089-1094. doi: 10.1016/j.bbrc.2014.06.123. Epub 2014 Jul 1.
30. Karstoft K, Pedersen BK. Skeletal muscle as a gene regulatory endocrine organ. Curr Opin Clin Nutr Metab Care. 2016 Jul;19(4):270-275. doi: 10.1097/ MCO.0000000000000283.
31. Seidler DG, Mohamed NA, Bocian C, et al. The role for decorin in delayed-type hypersensitivity. J Immunol. 2011 Dec 1 ;187(11):6108-6119. doi: 10.4049/jimmunol. 1100373. Epub 2011 Oct 31.
32. Kalamajski S, Oldberg A. The role of small leucine-rich proteoglycans in collagen fibrillogenesis. Matrix Biol. 2010 May;29(4):248-253. doi: 10.1016/j.matbio.2010.01.001. Epub 2010 Jan 18.
33. Järveläinen H, Puolakkainen P, Pakkanen S, et al. A role for decorin in cutaneous wound healing and angiogenesis. Wound Repair Regen. 2006 Jul-Aug; 14(4):443-452. doi: 10.1111/j.1743-6109.2006.00150.x
34. Merline R, Lazaroski S, Babelova A, et al. Decorin deficiency in diabetic mice: aggravation of nephropathy due to overexpression of profibrotic factors, enhanced apoptosis and mononuclear cell infiltration. J Physiol Pharmacol. 2009 Oct;60 Suppl 4:5-13.
35. Rentz TJ, Poobalarahi F, Bornstein P, et al. SPARC regulates processing of procollagen I and collagen fibrillogenesis in dermal fibroblasts. J Biol Chem. 2007 Jul 27;282(30):22062-22071. Epub 2007 May 23.
36. Delany AM, Kalajzic I, Bradshaw AD, et al. Osteonectin-null mutation compromises osteoblast formation, maturation, and survival. Endocrinology. 2003 Jun;144(6):2588-2596. doi: 10.1210/en.2002-221044
37. Machado do Reis L, Kessler CB, Adams DJ, et al. Accentuated osteoclastic response to parathyroid hormone undermines bone mass acquisition in osteonectin-null mice. Bone. 2008 Aug;43(2):264-273. doi: 10.1016/j. bone.2008.03.024. Epub 2008 Apr 13.
38. Boskey AL, Moore dJ, Amling M, et al. Infrared analysis of the mineral and matrix in bones of osteonectin-null mice and their wildtype controls. J Bone Miner Res. 2003 Jun;18(6):1005-1011. doi: 10.1359/jbmr.2003.18.6.1005
39. Mendoza-Londono R, Fahiminiya S, Majewski J, et al. Recessive osteogenesis imperfecta caused by missense mutations in SPARC. Am J Hum Genet. 2015 Jun 4;96(6):979-985. doi: 10.1016/j.ajhg.2015.04.021. Epub 2015 May 28.
40. Kapinas K, Lowther KM, Kessler CB, et al. Bone matrix osteonectin limits prostate cancer cell growth and survival. Matrix Biol. 2012 Jun;31(5):299-307. doi: 10.1016/j. matbio.2012.03.002. Epub 2012 Apr 16.
41. Aoi W, Naito Y, Takagi T, et al. A novel myokine, secreted protein acidic and rich in cysteine (SPARC), suppresses colon tumorigenesis via regular exercise. Gut. 2013 Jun;62(6):882-889. doi: 10.1136/gutjnl-2011-300776. Epub 2012 Jul 31.
42. Шишкин А.Н., Кирилюк Д.В. Дисфункция эндотелия у пациентов с прогрессирующими заболеваниями почек // Нефрология. - 2005. - Т. 9. - №2. - С. 16-22. [Shishkin AN, Kirilyuk DV. Endothelial dysfunction in patients with progressive renal disease. Nephrology. 2005;9(2): 16-22. (In Russ)
43. Nielsen AR, Pedersen BK. The biological roles of exercise-induced cytokines: IL-6, IL-8, and IL-15. Appl Physiol Nutr Metab. 2007 Oct;32(5):833-839. doi: 10.1139/H07-054. Review.
44. Nielsen AR, Mounier R, Plomgaard P, et al. Expression of interleukin-15 in human skeletal muscle effect of exercise and muscle fibre type composition. J Physiol. 2007 Oct 1;584(Pt 1):305-312. doi: 10.1113/jphysiol.2007.139618. Epub 2007 Aug 9.
45. Nielsen AR, Hojman P, Erikstrup C, et al. Association between interleukin-15 and obesity: interleukin-15 as a potential regulator of fat mass. J Clin Endocrinol Metab. 2008 Nov;93(11):4486-93. doi: 10.1210/jc.2007-2561. Epub 2008 Aug 12.
46. Quinn LS, Anderson BG, Strait-Bodey L, et al. Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. Am J PhysiolEndocrinolMetab. 2009 Jan;296(1):191-202. doi: 10.1152/ajpendo.90506.2008. Epub 2008 Nov 11.
47. Mattson MP, Maudsley S, Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 2004 Oct;27(10):589-594. doi: 10.1016/j.tins.2004.08.001
48. Tyler WJ, Alonso M, Bramham CR, et al. From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning. Learn Mem. 2002 Sep-Oct;9(5):224-237. doi: 10.1101/lm.51202. Review.
49. Connor B, Young D, Yan Q, et al. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res Mol Brain Res. 1997 Oct 3;49(1-2):71-81.
50. Laske C, Stransky E, Leyhe T, et al. Stage-dependent BDNF serum concentrations in Alzheimer's disease. J Neural Transm (Vienna). 2006 Sep; 113(9): 1217-1224. doi: 10.1007/ s00702-005-0397-y. Epub 2005 Dec 16.
51. Manni L, Nikolova V, Vyagova D. Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes. Int J Cardiol. 2005;102:169-171. doi: 10.1016/j. ijcard.2004.10.041.
52. Krabbe KS, Nielsen AR, Krogh-Madsen R, et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia. 2007;50:431-438. doi: 10.1007/s00125-006-0537-4. Epub 2006 Dec 7.
53. Karege F, Perret G, Bondolfi G, et al. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 2002;109:143-148.
54. Matthews VB, Aström MB, Chan MH, et al. Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinase. Diabetologia. 2009;52:1409-1418. doi: 10.1007/s00125-009-1364-1. Epub 2009 Apr 22.
55. Nieman DC, Henson DA, Smith LL, et al. Cytokine changes after marathon race. J Appl Physiol. 2001;91:109-114.
56. Akerström TC, Steensberg A, Keller P, et al. Exercise induces interleukin-8 expression in human skeletal muscle. J Physiol. 2005;563:507-516. doi: 10.1113/ jphysiol.2004.077610. Epub 2004 Dec 23.
57. Brandt C, Pedersen BK. The role of exercise-induced myokines in muscle homeostasis and the defense against chronic diseases. J Biomed Biotechnol. 2010;2010:520258. doi:10.1155/2010/520258. Epub 2010 Mar 9.
58. Гребенникова ТА., Белая Ж.Е., Рожинская Л.Я., и др. Эпигенетические аспекты остеопороза // Вестник РАМН. -2015. - Т. 5. - С. 541-548. [Grebennikova TA, Belaya ZhE, Rozhinskaya LYa, et al. Epigenetic Aspects of Osteoporosis. Vestnik RAMN. 2015;5:541-548. (In Russ)]. doi:10.15690/ vramn.v70.i5.1440.
Review
For citations:
Tsoriev T.T., White Zh.E., Rozhinskaya L.Ya. THE ROLE OF MYOKINES INTERSTITIAL INTERACTION AND REGULATION OF METABOLISM: A REVIEW OF LITERATURE. Osteoporosis and Bone Diseases. 2016;19(1):28-34. (In Russ.)